Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer

Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer

(1) Background: Understanding how advanced cancers evade host innate and adaptive immune opponents has led to cancer immunotherapy. Among several immunotherapeutic strategies, the reversal of immunosuppression mediated by regulatory T cells in the tumor microenvironment (TME) using blockers of immun...

Full description

Bibliographic Details
Main Authors: Kodchakorn Mahasongkram, Kantaphon Glab-ampai, Kanasap Kaewchim, Thanatsaran Saenlom, Monrat Chulanetra, Nitat Sookrung, Oytip Nathalang, Wanpen Chaicumpa
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Vaccines
Subjects:
cancer immunotherapy
bivalent scFvs-Fcγ antibodies
fusion protein
human single-chain antibody
OX40
OX40 agonistic antibodies
Online Access:https://www.mdpi.com/2076-393X/11/12/1826

Internet

https://www.mdpi.com/2076-393X/11/12/1826

Similar Items